Comparison between 31P MRS and 18F-FDG PET for response prediction in non-Hodgkin’s lymphoma

Mihaela Rata1, Nandita Desouza1, Michael Germuska1, Michael Partridge2, Martin O Leach1, and Geoffrey S Payne1

1MRI Unit, CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom, 2Radiotherapy and Imaging, CR-UK and EPSRC Cancer Imaging Centre, Institute of Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom

Introduction. In addition to defining disease extent, 18F PET (18F fluorodeoxyglucose positron emission tomography) has shown potential as a predictive biomarker in non-Hodgkin’s lymphomas (NHL) [1]. 31P MRS (31P magnetic resonance spectroscopy) has also demonstrated promise as a predictive biomarker [2]: early results suggest the phosphomonomester (PME) peak normalized by the total amount of β-NTP (nucleoside triphosphates) predict treatment response in tumors [3]. The purpose of this study therefore was to determine whether 18F PET uptake and PME/βNTP ratio are correlated in NHL in order to explore the relationship between glucose utilization and cellular energy metabolism in predicting treatment response.

Methods. 31P MRS was performed on a 1.5 T Siemens Avanto on a cohort of 10 NHL patients, within 7 days of the PET scan. The NHL subtypes were: 2 follicular lymphoma, 7 diffuse large B-cell lymphoma and one unknown. All 10 patients were treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) for 3 to 8 cycles. MR data were acquired from 15.6-125 ml voxel using [1H,31P] surface coils. Three orthogonal anatomical image sets (T2 steady state gradient echo, max FOV=400 mm, TR/TE=3.79/1.9, 12 slice of 7 mm thickness) were used for planning the [31P] spectra acquisition. The 3D [1H]-decoupled [31P] CSI protocol consisted of: TR/TE = 1000/2.3, 45° RF pulse, vector size 1024, 8x8x8 phase encoding steps, 2 averages, 1000 Hz spectral width, giving a total acquisition time ~17 min. MR data were processed using the jMRUI software [4], and the ratio between PME and total β-NTP was reported for the voxel over the tumour. The reported PET parameter was the maximum of the standardized uptake value (SUV) measured within the tumour, normalized by the mean of the SUV observed for the blood pool (left ventricle of heart).

Results and discussions. Figure 1 shows an example of 18F FDG uptake (top left) and the corresponding 31P MR spectrum (right) obtained from the voxel highlighted in the bottom left panel. The metabolites of interest were clearly detected in all tumour spectra: PME/β-NTP was successfully quantified for all 10 patients. The high quality of spectra was reflected in low residual of the fitting (standard deviation range 0.6-2.1). Normalized SUV_max and PME/βNTP ratios are summarised in figure 2. Non parametric tests found no correlation between the measured 18F FDG/ MRS parameters: Kendall tau (0.022), Spearman (0.0061).

Conclusion. Lack of correlation between normalized SUV_max and PME/βNTP ratios suggests that these parameters may contain complementary information regarding treatment outcome.

Acknowledgements. RMH radiographers, CRUK & EPSRC Cancer Imaging Centre, MRC and Department of Health (England) grants C1060/A10334 and C51/A7401, NCI (USA).

Figure 1. 18F FDG uptake in a NHL mass within the right breast (top left panel). 31P MR spectrum acquired from the same area is shown (right panels). The acronyms stand for: α, β, γ - nucleoside triphosphates, PCr - phosphocreatine, Pi - inorganic phosphate, PDE - phosphodiesters, PME - phosphomonoesters.

Figure 2. Relationship between SUV_max and PME/βNTP in NHL masses in 10 patients. Responders as assessed by RECIST criteria at 6 months are colour coded: red - complete response; orange – partial response; gray – 6-month time point not yet reached.